These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 25192260)
21. Discovery of cyclic acylguanidines as highly potent and selective beta-site amyloid cleaving enzyme (BACE) inhibitors: Part I--inhibitor design and validation. Zhu Z; Sun ZY; Ye Y; Voigt J; Strickland C; Smith EM; Cumming J; Wang L; Wong J; Wang YS; Wyss DF; Chen X; Kuvelkar R; Kennedy ME; Favreau L; Parker E; McKittrick BA; Stamford A; Czarniecki M; Greenlee W; Hunter JC J Med Chem; 2010 Feb; 53(3):951-65. PubMed ID: 20043696 [TBL] [Abstract][Full Text] [Related]
22. Assessing Scaffold Diversity of Kinase Inhibitors Using Alternative Scaffold Concepts and Estimating the Scaffold Hopping Potential for Different Kinases. Dimova D; Bajorath J Molecules; 2017 May; 22(5):. PubMed ID: 28467353 [TBL] [Abstract][Full Text] [Related]
23. Trends in kinase selectivity: insights for target class-focused library screening. Posy SL; Hermsmeier MA; Vaccaro W; Ott KH; Todderud G; Lippy JS; Trainor GL; Loughney DA; Johnson SR J Med Chem; 2011 Jan; 54(1):54-66. PubMed ID: 21128601 [TBL] [Abstract][Full Text] [Related]
24. Kinomics-structural biology and chemogenomics of kinase inhibitors and targets. Vieth M; Higgs RE; Robertson DH; Shapiro M; Gragg EA; Hemmerle H Biochim Biophys Acta; 2004 Mar; 1697(1-2):243-57. PubMed ID: 15023365 [TBL] [Abstract][Full Text] [Related]
25. Systematic comparison of competitive and allosteric kinase inhibitors reveals common structural characteristics. Hu H; Laufkötter O; Miljković F; Bajorath J Eur J Med Chem; 2021 Mar; 214():113206. PubMed ID: 33540355 [TBL] [Abstract][Full Text] [Related]
26. Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors. Hu H; Bajorath J Bioorg Med Chem; 2021 Jul; 41():116226. PubMed ID: 34082305 [TBL] [Abstract][Full Text] [Related]
27. Structure guided design of a series of sphingosine kinase (SphK) inhibitors. Gustin DJ; Li Y; Brown ML; Min X; Schmitt MJ; Wanska M; Wang X; Connors R; Johnstone S; Cardozo M; Cheng AC; Jeffries S; Franks B; Li S; Shen S; Wong M; Wesche H; Xu G; Carlson TJ; Plant M; Morgenstern K; Rex K; Schmitt J; Coxon A; Walker N; Kayser F; Wang Z Bioorg Med Chem Lett; 2013 Aug; 23(16):4608-16. PubMed ID: 23845219 [TBL] [Abstract][Full Text] [Related]
28. A data mining method to facilitate SAR transfer. Wassermann AM; Bajorath J J Chem Inf Model; 2011 Aug; 51(8):1857-66. PubMed ID: 21774471 [TBL] [Abstract][Full Text] [Related]
29. IRAK-4 inhibitors. Part 1: a series of amides. Buckley GM; Gowers L; Higueruelo AP; Jenkins K; Mack SR; Morgan T; Parry DM; Pitt WR; Rausch O; Richard MD; Sabin V; Fraser JL Bioorg Med Chem Lett; 2008 Jun; 18(11):3211-4. PubMed ID: 18474425 [TBL] [Abstract][Full Text] [Related]
30. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Erlanson DA; Arndt JW; Cancilla MT; Cao K; Elling RA; English N; Friedman J; Hansen SK; Hession C; Joseph I; Kumaravel G; Lee WC; Lind KE; McDowell RS; Miatkowski K; Nguyen C; Nguyen TB; Park S; Pathan N; Penny DM; Romanowski MJ; Scott D; Silvian L; Simmons RL; Tangonan BT; Yang W; Sun L Bioorg Med Chem Lett; 2011 May; 21(10):3078-83. PubMed ID: 21459573 [TBL] [Abstract][Full Text] [Related]
31. Systematic identification of scaffolds representing compounds active against individual targets and single or multiple target families. Hu Y; Bajorath J J Chem Inf Model; 2013 Feb; 53(2):312-26. PubMed ID: 23339619 [TBL] [Abstract][Full Text] [Related]
32. 970 million druglike small molecules for virtual screening in the chemical universe database GDB-13. Blum LC; Reymond JL J Am Chem Soc; 2009 Jul; 131(25):8732-3. PubMed ID: 19505099 [TBL] [Abstract][Full Text] [Related]
33. Kinase inhibitor data modeling and de novo inhibitor design with fragment approaches. Vieth M; Erickson J; Wang J; Webster Y; Mader M; Higgs R; Watson I J Med Chem; 2009 Oct; 52(20):6456-66. PubMed ID: 19791746 [TBL] [Abstract][Full Text] [Related]
34. Mining for bioactive scaffolds with scaffold networks: improved compound set enrichment from primary screening data. Varin T; Schuffenhauer A; Ertl P; Renner S J Chem Inf Model; 2011 Jul; 51(7):1528-38. PubMed ID: 21615076 [TBL] [Abstract][Full Text] [Related]
35. Recent Advances in Scaffold Hopping. Hu Y; Stumpfe D; Bajorath J J Med Chem; 2017 Feb; 60(4):1238-1246. PubMed ID: 28001064 [TBL] [Abstract][Full Text] [Related]
36. Quest for the rings. In silico exploration of ring universe to identify novel bioactive heteroaromatic scaffolds. Ertl P; Jelfs S; Mühlbacher J; Schuffenhauer A; Selzer P J Med Chem; 2006 Jul; 49(15):4568-73. PubMed ID: 16854061 [TBL] [Abstract][Full Text] [Related]
37. Chemical genetic approaches to kinase drug discovery. Gallion SL; Qian D Curr Opin Drug Discov Devel; 2005 Sep; 8(5):638-45. PubMed ID: 16159026 [TBL] [Abstract][Full Text] [Related]
38. Design and synthesis of potent and selective azaindole-based Rho kinase (ROCK) inhibitors. Schirok H; Kast R; Figueroa-Pérez S; Bennabi S; Gnoth MJ; Feurer A; Heckroth H; Thutewohl M; Paulsen H; Knorr A; Hütter J; Lobell M; Münter K; Geiss V; Ehmke H; Lang D; Radtke M; Mittendorf J; Stasch JP ChemMedChem; 2008 Dec; 3(12):1893-904. PubMed ID: 18973168 [TBL] [Abstract][Full Text] [Related]
39. Identification of 1,2,5-oxadiazoles as a new class of SENP2 inhibitors using structure based virtual screening. Kumar A; Ito A; Takemoto M; Yoshida M; Zhang KY J Chem Inf Model; 2014 Mar; 54(3):870-80. PubMed ID: 24512059 [TBL] [Abstract][Full Text] [Related]